Biotech Values

[caravon]

I have been invested in GILD from 1995. I was in and out few times. Now, I am out.

GILD is a good company but it never had a serious competition in its HIV business. Now, following an ENTA/AbbVie HCV approval, GILD for the first time will have a very serious competitor.

IMO, assuming AbbVie will not screw up the HCV marketing big time, ENTA shares will easily go well over $100.

May be I am old and blind but GILD's HCV product development/clinical trials created a huge opening for ENTA/AbbVie HCV marketing.